# BPC-157 vs TB-500: What Is the Difference?

BPC-157 and TB-500 are both studied in tissue repair, but they work on different parts of the job. This guide explains the difference in plain terms, why TB-500 is not the same as thymosin beta-4, and when buying them separately makes more sense than the blend. Supplied for in vitro research purposes only.

- Source: https://www.australianresearchpeptides.au/articles/bpc-157-vs-tb-500
- Reading time: 5 minute read
- Published: 2026-07-28
- Updated: 2026-09-02
- Publisher: Australian Research Peptides

---

## What Is the Difference Between BPC-157 and TB-500?

Both are studied in tissue repair, but they work on different parts of the job.

**BPC-157** is studied mainly for blood supply. It encourages new blood vessels to grow into damaged tissue, and prompts the cells that build connective tissue to get to work.

**TB-500** is studied mainly for cell movement. Cells need an internal scaffold to move around, and TB-500 acts on the protein that scaffold is built from.

A rough way to hold the difference: one brings in the supply line, the other moves the workforce.

_BPC-157 and TB-500 compared by size, origin and what each is studied for_

|  | BPC-157 | TB-500 |
| --- | --- | --- |
| Size | 15 amino acids | 7 amino acids |
| Where it comes from | A short section of a larger protein found in stomach fluid | A short section of a protein called thymosin beta-4 |
| Mainly studied for | New blood vessels, and building connective tissue | Cell movement into a wound |

## What Is BPC-157 Studied For?

Most of the published work is about getting blood to an injury. New blood vessels mean oxygen and nutrients reach the damaged area, and BPC-157 has been studied for its effect on that.

It also appears to affect how well repaired tissue is organised, not just how much of it there is. That is the difference between tissue that is patched and tissue that is rebuilt properly.

What stands out is the range of situations it has been studied in: tendon, ligament, muscle, burns, the gut lining and bone. That breadth is why it turns up in so many different research contexts. [The BPC-157 listing](https://www.australianresearchpeptides.au/products/bpc-157) carries the full sequence and the batch certificate.

## What Is TB-500 Studied For?

Cell movement. To move, a cell has to keep rebuilding its internal framework, and that framework is made of a protein called actin. TB-500 binds to actin, which is why it is studied for how cells travel into a wound.

It has also been studied for new blood-vessel growth, and in work reporting that repaired tendon could take more load before failing. [The TB-500 listing](https://www.australianresearchpeptides.au/products/tb-500) states which material is supplied.

## Is TB-500 the Same as Thymosin Beta-4?

No, and this is the single most useful thing to know before reading anything else about it.

Thymosin beta-4 is the full protein. TB-500 is a small piece cut out of it — seven amino acids out of forty-three.

That matters because the full protein does not do the same job all the way along its length. Different sections do different things:

- One section handles **cell movement** and wound healing. TB-500 _is_ that section.
- A different section, at the other end, is the part linked to **calming inflammation and reducing scarring**. TB-500 does not contain it.

So a study showing thymosin beta-4 reduces scarring is a study about a part of the protein that TB-500 does not have. The two are not interchangeable, and the difference is specific rather than vague.

Most “TB-500 research” is not about TB-500.

A search of the medical literature in August 2026 returned over a thousand papers on thymosin beta-4 and about twenty-five on TB-500 itself — and several of those twenty-five are laboratory method papers rather than studies of what it does. Treat any claim you read as being about the full protein unless the source shows otherwise.

## Separately or as a Blend?

The two are often sold together precisely because they do _not_ overlap. They act at different points in the same process, so research using both is common.

[The BPC-157 + TB-500 blend](https://www.australianresearchpeptides.au/products/bpc-157-tb-500) puts both into a single vial. That fixes the ratio between them and leaves one vial to prepare instead of two. Buying the two listings separately keeps them independent, which is what you want if the work needs one without the other. [Peptide types, categories and blends](https://www.australianresearchpeptides.au/articles/peptide-types-categories-blends) explains the trade-off in more detail.

## Has the Combination Been Studied Directly?

Once, in animals. A 2026 study transected and repaired the Achilles tendon in 32 rats and split them into four groups of eight: no treatment, BPC-157 alone, TB-500 alone, and both together. Treatment ran for four weeks by injection into the abdominal cavity.

The result that matters for anyone choosing between a blend and two separate vials is the plainest sentence in the paper: **combining the two conferred no additional benefit over either one alone**.

_What the 2026 rat Achilles tendon study reported for each treatment group_

| Group | Load the repaired tendon took before failing | Tissue architecture scores |
| --- | --- | --- |
| BPC-157 alone | Higher than untreated, but not by enough to be statistically significant | Better than untreated on the numbers, again short of significance on the totals |
| TB-500 alone | Higher than untreated, and the only group where that reached significance | Significantly better than untreated on both scoring systems used |
| Both together | Not significantly better than untreated | Significantly better than untreated on one of the two scoring systems |

So the combination was not inert — it beat doing nothing on one measure. It simply did not beat either peptide used on its own. The authors suggest the two may act on overlapping downstream pathways, and say directly that the idea needs testing rather than assuming.

What this does and does not settle.

It is one exploratory study, in 32 rats, over four weeks, by a route no laboratory buying a vial would replicate, and the authors describe their own findings as preliminary. It is not evidence that the blend is useless, and it is certainly not evidence about people. What it does do is remove the assumption that two peptides in one vial must do more than one — that assumption now has a direct test pointing the other way, and nothing pointing towards it.

The blend and BPC-157 on its own are both HPLC tested per batch, with the certificate published in the [CoA library](https://www.australianresearchpeptides.au/coa). Each listing shows its own current stock.

## Common Questions

### Is BPC-157 or TB-500 Better for Tissue Repair Research?

Neither is a better version of the other. They are studied at different points in the same process, so which one suits a piece of research depends entirely on what that research is measuring. No supplier can answer that question for you.

### What Is the Difference Between TB-500 and Thymosin Beta-4?

Thymosin beta-4 is a protein of 43 amino acids. TB-500 is a seven-amino-acid piece of it. The piece it contains is the part linked to cell movement and wound healing. The part linked to calming inflammation and reducing scarring sits elsewhere in the protein and is not included. So results reported for the full protein may depend on a section the fragment does not have.

### How Many Amino Acids Are in BPC-157 and TB-500?

BPC-157 is fifteen amino acids long. TB-500 is seven. Both are short enough to be made synthetically and checked by weight, which is what lets a certificate confirm the vial holds what the label says.

### Can I Buy BPC-157 and TB-500 Together in Australia?

Australian Research Peptides supplies the two together as a single pre-combined vial from within Australia, and each of them separately. The [blend listing](https://www.australianresearchpeptides.au/products/bpc-157-tb-500) shows its current stock.

All three forms discussed above are listed by Australian Research Peptides — BPC-157 and TB-500 as separate 10 mg vials, and the pre-combined blend in one — each HPLC-tested by batch and posted from Sydney. BPC-157 and the blend are in stock today; TB-500 is not.

## References

1. [Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. Journal of Applied Physiology 2011;110(3):774-80 (PMID 21030672)](https://pubmed.ncbi.nlm.nih.gov/21030672/)
2. [Biçer O, Adanir O, Güleryüz Y, et al. "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study." Joint Diseases and Related Surgery 2026;37(3):822-837 (PMID 42542926)](https://pubmed.ncbi.nlm.nih.gov/42542926/)
3. [Philp D, Badamchian M, Scheremeta B, et al. Wound Repair and Regeneration 2003;11(1):19-24 (PMID 12581423)](https://pubmed.ncbi.nlm.nih.gov/12581423/)
4. [Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. FASEB Journal 2003;17(14):2103-2105 (PMID 14500546)](https://pubmed.ncbi.nlm.nih.gov/14500546/)
5. [UniProt Knowledgebase entry P62328 (TYB4_HUMAN), thymosin beta-4 — flat-file record](https://rest.uniprot.org/uniprotkb/P62328.txt)
6. [PubChem Compound CID 9941957 (BPC-157)](https://pubchem.ncbi.nlm.nih.gov/compound/9941957)
7. [PubChem Compound CID 62707662 (TB-500, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH)](https://pubchem.ncbi.nlm.nih.gov/compound/62707662)

## Related guides

- [Retatrutide: What It Is and What the Trials Show](https://www.australianresearchpeptides.au/articles/retatrutide-mechanism-and-trial-record)
- [Tesamorelin: What It Is and Who the Trials Studied](https://www.australianresearchpeptides.au/articles/tesamorelin-ghrh-analogue-research)

## Related compounds

- [BPC-157](https://www.australianresearchpeptides.au/products/bpc-157)
- [TB-500](https://www.australianresearchpeptides.au/products/tb-500)
- [BPC-157 + TB-500](https://www.australianresearchpeptides.au/products/bpc-157-tb-500)

---

_Plain-text version of https://www.australianresearchpeptides.au/articles/bpc-157-vs-tb-500. The web page is the canonical version of this article._

_All products supplied by Australian Research Peptides are for in vitro research purposes only._